throbber
Case 2:15-cv-01455-WCB Document 510-3 Filed 10/10/17 Page 1 of 4 PageID #: 25579
`Case 2:15-cv-01455-WCB Document 510-3 Filed 10/10/17 Page 1 of 4 PageID #: 25579
`
`EXHIBIT G
`
`

`

`Allergan and Saint Regis Mohawk Tribe… | Saint Regis Mohawk Tribe
`Page 1 of 3
`Case 2:15-cv-01455-WCB Document 510-3 Filed 10/10/17 Page 2 of 4 PageID #: 25580
`
`Home (/)
`
`Jobs (/employment) News (/news)
`
`Events (/events) Publications (/publications) About (/about-the-tribe) Contact (/contact)
`
`Intranet (/intranet)
`
`(cid:1) (/search)
`
`Tribal Council
`
`Programs
`
`Enterprises (/enterprises)
`
`Support Services
`
`Oversight Bodies (/committees)
`
`Independent Officials
`
`(https://www.srmt-nsn.gov/)
`
`News (/news)
`
`Current News (/news)
`
`News Archive (/news/archive)
`
`Allergan and Saint Regis Mohawk Tribe
`Announce Agreements Regarding
`RESTASIS® Patents
`
`Sep 8, 2017
`
`The Tribe Is Filing Motion to Dismiss Inter Partes Review of RESTASIS Patents Based on its Sovereign
`
`Immunity
`
`DUBLIN, IRELAND –September 8, 2017– Allergan plc (NYSE: AGN), a leading global pharmaceutical
`
`company, and the Saint Regis Mohawk Tribe today announced that the Tribe now owns all Orange
`
`Book-listed patents for RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%, and that Allergan has
`
`been granted exclusive licenses in the patents related to the product. The Tribe, a recognized
`
`sovereign tribal government, is filing a motion to dismiss the ongoing inter partes review (IPR) of the
`
`RESTASIS® patents based on their sovereign immunity from IPR challenges.The agreement with the
`
`Tribe has no impact on the pending abbreviated new drug application (ANDA) patent litigations
`
`regarding the RESTASIS® patent family which recently completed a five-day trial in Federal District
`
`Court in Marshall, Texas.
`
`“The Saint Regis Mohawk Tribe and its counsel approached Allergan with a sophisticated
`
`opportunity to strengthen the defense of our RESTASIS® intellectual property in the upcoming inter
`
`partes reviewproceedings before the Patent Trial and Appeal Board,” said Bob Bailey, Allergan’s
`
`Chief Legal Officer. “Allergan evaluated this approach closely, with expert counsel in patent and
`
`sovereign immunity law.This included a thorough review of recent case law such as Covidien LP v.
`
`University of Florida Research Foundation Inc.and Neochord, Inc. v. University of Maryland, in which
`
`https://www.srmt-nsn.gov/news/2017/allergan-and-saint-regis-mohawk-tribe-announce-a...
`
`10/10/2017
`
`

`

`Allergan and Saint Regis Mohawk Tribe… | Saint Regis Mohawk Tribe
`Page 2 of 3
`Case 2:15-cv-01455-WCB Document 510-3 Filed 10/10/17 Page 3 of 4 PageID #: 25581
`
`the PTAB dismissed IPR proceedings against the universities based upon their claims of sovereign
`
`immunity. We are impressed with the Tribe’s thoughtful and enterprising approach, which will allow
`
`them to achieve their goals of self-reliance and help them address the most urgent needs in their
`
`community.”
`
`In a unified statement about the agreement with Allergan, the Saint Regis Mohawk Tribal Council
`
`stated, “This is a viable and sound opportunity for the Saint Regis Mohawk Tribe to enter into the
`
`patent, technology and research sector as part of our overall economic diversification strategy. We
`
`realize that we cannot depend solely on casino revenues and, in order for us to be self-reliant, we
`
`must enter into diverse business sectors to address the chronically unmet needs of the Akwesasne
`
`community; such as housing, employment, education, healthcare, cultural and language
`
`preservation.”
`
`Under the terms of the agreement, the Tribe will receive $13.75 million upon execution of the
`
`agreement. Additionally, the Tribe will be eligible to receive $15 million in annual royalties.
`
`The patents transferred to the Tribe include United States Patent Nos. 8,629,111; 8,633,162;
`
`8,642,556; 8,648,048; 8,685,930 and 9,248,191. The patents are listed in the Orange Book for
`
`RESTASIS® and expire on August 27, 2024.
`
`About Allergan plc
`
`Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical
`
`company and a leader in a new industry model – Growth Pharma. Allergan is focused on
`
`developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical
`
`and regenerative medicine products for patients around the world.
`
`Allergan markets a portfolio of leading brands and best-in-class products for the central nervous
`
`system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology
`
`and anti-infective therapeutic categories.
`
`Allergan is an industry leader in Open Science, a model of research and development, which defines
`
`our approach to identifying and developing game-changing ideas and innovation for better patient
`
`care. With this approach, Allergan has built one of the broadest development pipelines in the
`
`pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.
`
`Allergan’s success is powered by our more than 18,000 global colleagues’ commitment to being Bold
`
`for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and
`
`patients around the world by always doing what is right.
`
`With commercial operations in approximately 100 countries, Allergan is committed to working with
`
`physicians, healthcare providers and patients to deliver innovative and meaningful treatments that
`
`help people around the world live longer, healthier lives every day.
`
`For more information, visit Allergan’s website at (http://www.allergan.com/)www.Allergan.com
`
`(http://www.Allergan.com).
`
`About Saint Regis Mohawk Tribe:
`
`The Saint Regis Mohawk Tribal Council is the duly elected and U.S. federally recognized government
`
`of the Saint Regis Mohawk People.
`
`For more information, visit the Saint Regis Mohawk Tribe’s website at (http://www.srmt-nsn.gov/)
`
`www.srmt-nsn.gov (http://www.srmt-nsn.gov).
`
`Forward-Looking Statement
`
`Statements contained in this press release that refer to future events or other non-historical facts
`
`are forward-looking statements that reflect Allergan’s current perspective on existing trends and
`
`information as of the date of this release. Actual results may differ materially from Allergan’s
`
`https://www.srmt-nsn.gov/news/2017/allergan-and-saint-regis-mohawk-tribe-announce-a...
`
`10/10/2017
`
`

`

`Allergan and Saint Regis Mohawk Tribe… | Saint Regis Mohawk Tribe
`Page 3 of 3
`Case 2:15-cv-01455-WCB Document 510-3 Filed 10/10/17 Page 4 of 4 PageID #: 25582
`
`current expectations depending upon a number of factors affecting Allergan’s business. These
`
`factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or
`
`actions, if any; the impact of competitive products and pricing; market acceptance of and continued
`
`demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and
`
`uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange
`
`Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended
`
`December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30,
`
`2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update
`
`these forward-looking statements.
`
`Office Of Technology Research And Patents FAQS (https://www.srmt-
`
`nsn.gov/_uploads/site_files/Office-of-Technology-Research-and-Patents-FAQs.pdf)
`
`Share 4
`
`Working Together Today to Build a Better
`Tomorrow
`
`Ska’tne ionkwaio’te ón:wa wenhniserá:te ne sén:ha
`aioianerénhake ne enióhrhen’ne
`
`Copyright Saint Regis Mohawk Tribe. Site by GARRANT (https://www.garrant.com).
`
`Saint Regis Mohawk Tribe
`
`412 State Route 37
`
`Akwesasne, NY 13655
`
`Phone: 518-358-2272 Fax: 518.358.3203
`
`Saint Regis Mohawk Health Service
`
`Phone: 518.358.3141 Fax: 518.358.6245
`
`(cid:2)
`(https://www.facebook.com/SaintRegisMohawkTribe/)
`(cid:3) (https://twitter.com/srm_tribe)
`(cid:4)
`(https://www.instagram.com/srmtribe/)
`(cid:5)
`(https://www.youtube.com/channel/UCMOdZi7JqbaqwqYrf1uhawQ)
`
`https://www.srmt-nsn.gov/news/2017/allergan-and-saint-regis-mohawk-tribe-announce-a...
`
`10/10/2017
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket